Today, health-care analysts Brenton Flynn and David Williamson discuss one kidney cancer drug with interesting recent data. GlaxoSmithKline's drug was proven as effective as the drug's nearest rival. 

While this is certainly good news, David cautions that the kidney cancer drug space is becoming increasingly competitive, and he doesn't believe Glaxo's drug is poised to take the sector crown any time soon. 

When it comes to do-or-die businesses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.